Salud financiera de hoja de balance de NATCO Pharma
Salud financiera controles de criterios 6/6
NATCO Pharma tiene un patrimonio de accionistas total de ₹58.5B y una deuda total de ₹3.7B, lo que sitúa su ratio deuda-patrimonio en 6.3%. Sus activos y pasivos totales son ₹69.1B y ₹10.5B respectivamente. El BAIT de NATCO Pharma es de ₹19.7B, por lo que su ratio de cobertura de intereses es de 97.5. Tiene efectivo e inversiones a corto plazo que ascienden a ₹18.5B.
Información clave
6.3%
Ratio deuda-patrimonio
₹3.71b
Deuda
| Ratio de cobertura de intereses | 97.5x |
| Efectivo | ₹18.49b |
| Patrimonio | ₹58.53b |
| Total pasivo | ₹10.53b |
| Activos totales | ₹69.06b |
Actualizaciones recientes sobre salud financiera
NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Recent updates
We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹40.2B) de NATCOPHARM superan a sus pasivos a corto plazo (₹9.7B).
Pasivo a largo plazo: Los activos a corto plazo de NATCOPHARM (₹40.2B) superan a sus pasivos a largo plazo (₹804.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: NATCOPHARM tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de NATCOPHARM ha pasado de 11.1% a 6.3% en los últimos 5 años.
Cobertura de la deuda: La deuda de NATCOPHARM está bien cubierta por el flujo de caja operativo (326.4%).
Cobertura de intereses: Los pagos de intereses de la deuda de NATCOPHARM están bien cubiertos por el BAIT (97.5x cobertura).